Bryce Point Capital LLC Invests $495,000 in NeoGenomics, Inc. $NEO

Bryce Point Capital LLC acquired a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 64,084 shares of the medical research company’s stock, valued at approximately $495,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NEO. Headlands Technologies LLC acquired a new stake in shares of NeoGenomics in the 2nd quarter worth approximately $32,000. Capstone Financial Advisors Inc. acquired a new stake in NeoGenomics in the second quarter worth approximately $73,000. Captrust Financial Advisors acquired a new stake in NeoGenomics in the second quarter worth approximately $75,000. Gamco Investors INC. ET AL bought a new position in NeoGenomics during the 2nd quarter valued at $80,000. Finally, FORA Capital LLC acquired a new position in shares of NeoGenomics during the 2nd quarter valued at $84,000. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Stock Down 0.6%

Shares of NASDAQ:NEO opened at $11.35 on Tuesday. The firm has a 50 day simple moving average of $12.24 and a 200 day simple moving average of $9.86. NeoGenomics, Inc. has a 52 week low of $4.72 and a 52 week high of $14.73. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.62 and a current ratio of 3.91. The company has a market cap of $1.47 billion, a PE ratio of -12.90 and a beta of 1.58.

Insider Buying and Selling at NeoGenomics

In related news, COO Warren Stone sold 22,128 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $12.50, for a total value of $276,600.00. Following the completion of the sale, the chief operating officer directly owned 121,631 shares of the company’s stock, valued at approximately $1,520,387.50. This represents a 15.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Alicia C. Olivo sold 20,916 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $12.00, for a total value of $250,992.00. Following the completion of the transaction, the executive vice president owned 31,083 shares in the company, valued at $372,996. This represents a 40.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

NEO has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeoGenomics in a research note on Monday, December 29th. TD Cowen restated a “buy” rating on shares of NeoGenomics in a research report on Wednesday, January 7th. Leerink Partners set a $14.00 price objective on shares of NeoGenomics in a research note on Tuesday, October 28th. Zacks Research raised shares of NeoGenomics from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 12th. Finally, Needham & Company LLC restated a “buy” rating and issued a $14.00 price target on shares of NeoGenomics in a research report on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $12.00.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.